Keytruda should lose stomach cancer indication, says ODACThe FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted to strip Merck & Co’s Keytruda of its accelerated Share XKeytruda should lose stomach cancer indication, says ODAChttps://pharmaphorum.com/news/keytruda-should-lose-stomach-cancer-indication-says-odac/
FDA looks at pulling speedy approvals for three cancer drugsFDA advisors will scrutinise three cancer immunotherapies granted conditional approvals at a three-day meeting this week, to see Share XFDA looks at pulling speedy approvals for three cancer drugshttps://pharmaphorum.com/news/fda-looks-at-pulling-speedy-approvals-for-three-cancer-drugs/
BMS’ deucravacitinib psoriasis pill could launch next year after outperforming Amgen’s rivalBristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in Share XBMS’ deucravacitinib psoriasis pill could launch next year after outperforming Amgen’s rivalhttps://pharmaphorum.com/news/bms-deucravacitinib-psoriasis-pill-could-launch-next-year-after-outperforming-amgens-rival/
FDA approves BMS’ multiple myeloma CAR-T AbecmaThe FDA has approved Bristol-Myers Squibb’s Abecma (idecabtagene vicleucel) for multiple myeloma, the first cell therapy to treat Share XFDA approves BMS’ multiple myeloma CAR-T Abecmahttps://pharmaphorum.com/news/fda-approves-bms-multiple-myeloma-car-t-abecma/
Merck gets a leg-up for Keytruda in first-line kidney cancerNew phase 3 data have shored up the position of Merck & Co’s cancer immunotherapy Keytruda in the Share XMerck gets a leg-up for Keytruda in first-line kidney cancerhttps://pharmaphorum.com/news/merck-gets-a-leg-up-for-keytruda-in-first-line-kidney-cancer/
Heat Bio’s shares ignite on Opdivo combination data in NSCLCThe pairing of Heat Biologics’ lead drug HS-110 with Bristol-Myers Squibb’s blockbuster checkpoint inhibitor Opdivo has boosted survival Share XHeat Bio’s shares ignite on Opdivo combination data in NSCLChttps://pharmaphorum.com/news/heat-bios-shares-ignite-on-opdivo-combination-data-in-nsclc/
BMS finally gets FDA OK for liso-cel, sets $410k launch priceBristol-Myers Squibb finally has FDA approval for its CAR-T therapy liso-cel, which has been cleared by the US Share XBMS finally gets FDA OK for liso-cel, sets $410k launch pricehttps://pharmaphorum.com/news/bms-finally-gets-fda-ok-for-liso-cel-sets-410k-launch-price/
BMS eyes May FDA verdict for MS drug Zeposia in ulcerative colitisBristol-Myers Squibb’s commercial hopes for new multiple sclerosis drug Zeposia have yet to bear fruit thanks to the Share XBMS eyes May FDA verdict for MS drug Zeposia in ulcerative colitishttps://pharmaphorum.com/news/bms-eyes-may-fda-verdict-for-ms-drug-zeposia-in-ulcerative-colitis/
NICE rejects BMS’ Zeposia MS pill in provisional guidanceNICE has said that the NHS should not fund Bristol-Myers Squibb’s multiple sclerosis pill Zeposia (ozanimod) for relapsing Share XNICE rejects BMS’ Zeposia MS pill in provisional guidancehttps://pharmaphorum.com/market-access-2/nice-rejects-bms-zeposia-ms-pill-in-provisional-guidance/
